Clinical Trials

268 enrolled

Head and Neck Neoplasms

NCT06592599 2026-02-10

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

24 enrolled

Nasopharyngeal Carcinoma

NCT07290621 2026-02-06

Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer

30 enrolled

Oropharyngeal Neoplasms

NCT07136519 2025-08-22

Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma

30 enrolled

Nasopharyngeal Carcinoma

NCT07110558 2025-08-07

PUPA

59 enrolled

Nasopharyngeal Carcinoma

NCT07088211 2025-07-31

Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC

39 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05147844 2025-07-14

Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

NCT06940180 2025-06-26

Toripalimab With Chemotherapy for Sinus Cancer

20 enrolled

Sinonasal undifferentiated carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Paranasal Sinus Neoplasms

NCT06987123 2025-05-23

TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial

62 enrolled

Nasopharyngeal Carcinoma

NCT06912711 2025-05-21

TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

70 enrolled

Nasopharyngeal Carcinoma

NCT06861712 2025-04-25

Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer

50 enrolled

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04517214 2025-04-02

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

100 enrolled

Nasopharyngeal Carcinoma

NCT06851247 2025-02-28

GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

47 enrolled

Nasopharyngeal Carcinoma

NCT04996758 2024-12-12

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

Phase 2 Completed

Nasopharyngeal Carcinoma, Recurrence

NCT06323239 2024-08-20

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

148 enrolled

Nasopharyngeal Carcinoma

NCT06378177 2024-06-27

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

64 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06151743 2024-04-30

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma

32 enrolled

Locally Advanced Hypopharyngeal Carcinoma

NCT05773079 2024-04-01

Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma

28 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06081582 2023-10-13

Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC

33 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06039631 2023-09-15

Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer

82 enrolled

Hypopharyngeal Neoplasms, Laryngeal Neoplasms

NCT05993858 2023-08-15

PC-1

33 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04807140 2023-04-14

Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)

57 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05813626 2023-04-14

Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

89 enrolled

Nasopharyngeal Carcinoma

NCT05229315 2023-04-13

PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

45 enrolled

Nasopharyngeal Carcinoma

NCT05803915 2023-04-07

Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy

57 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04405622 2023-02-06

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

21 enrolled

Nasopharyngeal Carcinoma

NCT05628922 2022-11-29

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

198 enrolled

Nasopharyngeal Neoplasms

NCT05484375 2022-08-02

Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment

Nasopharyngeal Carcinoma

NCT05420597 2022-06-15

Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma

61 enrolled

Hypopharyngeal Neoplasms, Laryngeal Neoplasms

NCT04995120 2022-01-18

INSIGHT

42 enrolled

Hypopharyngeal Neoplasms, Laryngeal Neoplasms

NCT04992988 2021-08-20

Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial

Nasopharyngeal Carcinoma

NCT04955886 2021-07-09

Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

14 enrolled

Nasopharyngeal Carcinoma

NCT04825938 2021-04-28

Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Head & NeckOther neoplasm

15 enrolled

Salivary Gland Malignant Neoplasms

NCT04523883 2021-04-15

IMPORT

316 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04624308 2020-11-10

Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCC

81 enrolled

Hypopharyngeal Neoplasms

NCT04524884 2020-08-24

Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

10 enrolled

Thyroid Neoplasms

NCT04447326 2020-06-25

Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma

106 enrolled

Nasopharyngeal Carcinoma

NCT04164238 2019-11-15

Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients

90 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04126460 2019-10-15

RePASS

41 enrolled